Clinical implications of CYP2C19 polymorphism for tailor-made pharmacotherapy

International Congress Series

Volumn 1244, Issue C, 2002, Pages 41-49

  Sohn, Dong Ryul ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Clinical impacts; CYP2C19; Pharmacotherapy; Polymorphism

Indexed keywords

EID: 13944282356     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(02)00533-2     Document Type: Article

References (37)

1. Kalow, W., The genetic defect of mephenytoin hydroxylation. Xenobiotica 16 (1986), 379-389.
2. Küpfer, A., Desmond, P.V., Schenker, S., Branch, R.A., Stereospecific metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J. Pharmacol. Exp. Ther. 221 (1982), 590-597.
3. Küpfer, A., Desmond, P.V., Patwardhan, R., Schenker, S., Branch, R.A., Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin. Pharmacol. Ther. 35 (1984), 33-39.
4. Wedlund, P.J., Aslanian, W.S., Jacqz, E., McAllister, C.B., Branch, R.A., Wilkinson, G.R., Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J. Pharmacol. Exp. Ther. 234 (1985), 662-669.
5. Inaba, T., Jurima, M., Kalow, W., Family studies of mephenytoin hydroxylation deficiency. Am. J. Hum. Genet. 38 (1986), 768-772.
6. Küpfer, A., Preisig, R., Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26 (1984), 753-759.
7. Wedlund, P.J., Aslanian, W.S., McAllister, C.B., Wilkinson, G.R., Branch, R.A., Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36 (1984), 773-780.
8. Balian, J.D., Sukhova, N., Harris, J.W., Hewett, J., Pickle, L., Goldstein, J.A., Woosley, R.L., Flockhart, D.A., The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther. 57 (1995), 662-669.
9. Andersson, T., Regårdh, C.-G., Lou, Y.C., Zhang, Y., Dahl, M.-L., Bertilsson, L., Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2 (1992), 25-31.
10. Sohn, D.-R., Kobayashi, K., Chiba, K., Lee, K.-H., Shin, S.-G., Ishizaki, T., Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J. Pharmacol. Exp. Ther. 262 (1992), 1195-1202.
11. Jacqz, E., Dulac, H., Mathieu, H., Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur. J. Clin. Pharmacol. 35 (1988), 167-171.
12. Sohn, D.-R., Kusaka, M., Ishizaki, T., Shin, S.-G., Jang, I.-J., Shin, J.-G., Chiba, K., Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin. Pharmacol. Ther. 52 (1992), 160-169.
13. Horai, Y., Nakano, M., Ishizaki, T., Ishikawa, K., Zhou, H.-H., Zhou, B.-J., Liao, C.-L., Zhang, L.-M., Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese vs. mainland Chinese. Clin. Pharmacol. Ther. 46 (1989), 198-207.
14. Goldstein, J.A., de Morais, S.M.F., Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4 (1994), 285-299.
15. de Morais, S.M.F., Wilkinson, G.R., Blaisdell, J., Meyer, U.A., Nakamura, K., Goldstein, J.A., Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46 (1994), 594-598.
16. de Morais, S.M.F., Wilkinson, G.R., Blaisdell, J., Nakamura, K., Meyer, U.A., Goldstein, J.A., The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269 (1994), 15419-15422.
17. Brøsen, K., deMorais, S.M.F., Meyer, U.A., Goldstein, J.A., A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5 (1995), 312-317.
18. Kubota, T., Chiba, K., Ishizaki, T., Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60 (1996), 661-666.
19. Dalén, P., Alvan, G., Wakelkamp, M., Olsen, H., Formation of meprobamate from carisoprodol is catalysed by CYP2C19. Pharmacogenetics 6 (1996), 387-394.
20. Sindrup, S.H., Brøsen, K., Hansen, M.G.H., Aaes-Jørgensen, T., Overø, K.F., Gram, L.F., Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 15 (1993), 11-17.
21. Bertilsson, L., Henthorn, T.K., Sanz, E., Tybring, G., Säwe, J., Villén, T., Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther. 45 (1989), 348-355.
22. Knodell, R.G., Dubey, R.K., Wilkinson, G.R., Guengerich, F.P., Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J. Pharmacol. Exp. Ther. 245 (1988), 845-849.
23. Skjelbo, E., Brøsen, K., Hallas, J., Gram, L.F., The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49 (1991), 18-23.
24. Sohn, D.-R., Kwon, J.T., Kim, H.K., Ishizaki, T., Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotypic status. Clin. Pharmacol. Ther. 61 (1997), 574-582.
25. Küpfer, A., Branch, R.A., Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation polymorphism. Clin. Pharmacol. Ther. 38 (1985), 414-418.
26. Gram, L.F., Guentert, T.W., Grange, S., Vistisen, K., Brøsen, K., Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin. Pharmacol. Ther. 57 (1995), 670-677.
27. Ward, S.A., Helsby, N.A., Skjelbo, E., Brøsen, K., Gram, L.F., Breckenridge, A.M., The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br. J. Clin. Pharmacol. 31 (1991), 689-692.
28. Ward, S.A., Walle, T., Walle, U.K., Wilkinson, G.R., Branch, R.A., Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin. Pharmacol. Ther. 45 (1989), 72-79.
29. Goedde, H.W., Ethnic differences in reactions to drugs and other xenobiotics: outlook of a geneticist. Kalow, W., Goedde, H.W., Agarwal, D.P., (eds.) Ethnic Differences in Reactions to Drugs and Xenobiotics, 1986, Alan R. Liss, New York, 9-20.
30. Wilkinson, G.R., Guengerich, F.P., Branch, R.A., Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43 (1989), 53-76.
31. Ghoneim, M.M., Korttila, K., Chiang, C.-K., Jacobs, L., Schoenwald, R.D., Mewaldt, S.P., Kayaba, K.-O., Diazepam effects and kinetics in Caucasians and Orientals. Clin. Pharmacol. Ther. 29 (1981), 749-756.
32. Kumana, C.R., Lauder, I.J., Chan, M., Lin, H.J., Differences in diazepam pharmacokinetics in Chinese and White Caucasians—relation to body lipid stores. Eur. J. Clin. Pharmacol. 32 (1987), 211-215.
33. Zhang, Y., Reviriego, J., Lou, Y.Q., Sjöqvist, F., Bertilsson, L., Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin. Pharmacol. Ther. 48 (1990), 496-502.
34. Bertilsson, L., Kalow, W., Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations?. Clin. Pharmacol. Ther. 53 (1993), 608-610.
35. Clissold, S.P., Campoli-Richards, D.M., Omeprazole: an updated review. Drugs 32 (1986), 1-41.
36. Andersson, T., Andrén, K., Cederberg, C., Langeström, P.-O., Lundborg, P., Skånberg, I., Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol. 29 (1990), 557-563.
37. Ishizaki, T., Sohn, D.-R., Kobayashi, K., Chiba, K., Lee, K.-H., Shin, S.-G., Andersson, T., Regårdh, C.-G., Lou, Y.-C., Zhang, Y., Dahl, M.-L., Bertilsson, L., Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug. Monit. 16 (1994), 214-215.